Clinical Trial: Sildenafil for PNTM Infection
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Sildenafil in Patients With Pulmonary Nontuberculous Mycobacterial Infection
Brief Summary:
Background:
- Pulmonary nontuberculous mycobacterial (PNTM) infection is caused by a common type of bacteria in the environment. Although PNTM infection is most common in people with lung diseases, it can also affect healthy people. It can be difficult to treat, and affects parts of the body other than the lungs. For example, PNTM may affect the cilia, the hair-like structures inside the nose and lungs that help move dirt and debris out of the body.
- Ciliary beat frequency (CBF) is a measurement of how fast cilia move. People with PNTM infection have a lower CBF than healthy people. Nitric oxide (NO) is a gas in the body that may affect CBF. People with PNTM infection produce lower amounts of NO in their noses than healthy people. Researchers want to see if a drug called sildenafil can increase NO production and CBF. If sildenafil can improve these measurements, it may be a useful treatment for PNTM infection.
Objectives:
- To study the effect of sildenafil on CBF and NO levels in people with PNTM infection.
Eligibility:
- Individuals at least 18 years of age who have PNTM infection.
- Participants must be enrolled in a related National Institutes of Health study on bacterial infections. The study is Natural History, Genetics, Phenotype and Treatment of Mycobacterial Infections.
Design:
- Participants will be screened with a physical exam and medical history. They will also have heart and lung function tests,
